Ovid Therapeutics

Ovid Therapeutics, Inc. is a biopharmaceutical company, engaged in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtually in the “Orphan Neuro and Neuromuscular” panel discussion at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

– Ovid to License Gaboxadol to Healx –

Healx and Ovid Therapeutics to Enter Strategic Partnership

AstraZeneca

Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small molecules targeting the KCC2 transporter, including a lead candidate, OV350.  The Company seeks to optimize and accelerate the development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions.

Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the company has entered into an exclusive license agreement with AstraZeneca for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate, OV350. The company seeks to optimize and accelerate development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions.

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today provided a business update and reported corporate highlights and financial results for the quarter ended September 30, 2021.

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) --  Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today reported financial results for the quarter ended June 30, 2021. The Company also provided an overview of recently announced leadership appointments that will guide and execute its strategy.

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

Diebold Nixdorf Inc

Vontier Corporation

In order to increase your chances of beating the market, one method is to choose stocks that rank highly according to the "Magic Formula" criteria.

A Trio of Magic Formula Stock Picks

Dr. Michael Poole to Join the Board of Directors

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at the Ladenburg Thalmann 2021 Healthcare Conference on Wednesday, July 14, 2021 at 9:30 a.m. ET.

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

There are promising results for OV-935 in patients with Dravet Syndrome, with questionable results in patients with Lennox-Gastaut Syndrome (LGS). Pipeline drug OV-935 shows high revenue potential.

Ovid Therapeutics: Good Entry Point For Investors

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board.

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A.

Regeneron Pharmaceuticals

Repligen

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the quarter ended March 31, 2021 and provided an overview of the Company's recent progress.

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 9:10 a.m. ET.

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Allied Esports Entertainment Inc

Cinedigm

ION Geophysical

Nokia

OrganiGram Holdings Inc.

trivago

Helios and Matheson Analytics

The odds of bankrupt HMNY stock getting acquired may be slim, but for these seven other Reddit penny stocks it's definitely a possibility. The post HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover appeared first on InvestorPlace.

HMNY Stock & 7 Other Reddit Penny Stocks Hoping for a Takeover

Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The company says that while OV101 was well tolerated, with no significant safety signals observed, the company believes that efficacy outcomes observed in these trials do not support its further development.

Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological Conditions

Aikido Pharma Inc.

Iterum Therapeutics Plc

T2 Biosystems

Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks To Watch That Are Heating Up This Month

The stock price of Ovid Therapeutics Inc. (NASDAQ: OVID) increased by over 5% pre-market. This is why it happened.

OVID Stock Price Increased Over 5% Pre-Market: Why It Happened

AIM ImmunoTech Inc

Asensus Surgical

Celsion

iBio

Jaguar Health

Rigel Pharmaceuticals

VBI Vaccines

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

8 Biotech Penny Stocks for Investors to Watch

Ovid Therapeutics (OVID) stock is soaring higher on Wednesday after announcing a massive deal with Takeda Pharmaceutical (TKPHF). The post OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today appeared first on InvestorPlace.

OVID Stock News: The Big Deal That Has Ovid Therapeutics Rocketing Higher Today

KemPharm

Sorrento Therapeutics Inc

Aquestive Therapeutics Inc

Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesday's premarket session. Here's what investors need to know.

Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying

Takeda Pharmaceutical

Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). Under this new agreement, Takeda will develop and commercialize soticlestat globally, and Ovid will no longer have any financial obligation to Takeda under the original collaboration agreement announced in 2017.

Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes

The stock price of Ovid Therapeutics Inc (NASDAQ: OVID) increased by over 60% pre-market. This is why it happened.

OVID Stock Price Increases Over 60% Pre-Market: Why It Happened

OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

News for Ovid Therapeutics Stock (OVID)